Shares of CureVac (NASDAQ:CVAC - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $2.99, but opened at $2.86. CureVac shares last traded at $2.92, with a volume of 97,591 shares changing hands.
Analyst Ratings Changes
Separately, JMP Securities reaffirmed a "market outperform" rating and set a $16.00 price objective on shares of CureVac in a research note on Monday, September 16th.
View Our Latest Stock Report on CureVac
CureVac Price Performance
The stock has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $3.19. The company has a market cap of $642.54 million, a PE ratio of 5.22, a price-to-earnings-growth ratio of 0.24 and a beta of 2.59. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05.
Institutional Trading of CureVac
A number of institutional investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. purchased a new position in shares of CureVac in the second quarter valued at $8,237,000. Jane Street Group LLC lifted its holdings in shares of CureVac by 239.0% in the third quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock valued at $235,000 after purchasing an additional 55,867 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in shares of CureVac by 99.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company's stock worth $147,000 after purchasing an additional 21,999 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of CureVac by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company's stock worth $127,000 after purchasing an additional 16,792 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in CureVac during the 2nd quarter valued at $108,000. Hedge funds and other institutional investors own 17.26% of the company's stock.
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
See Also
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
